Why the Sampling Phase Matters
An oral concentration measured during the rise toward peak concentration contains different information from one measured well into the decline. Early observations can be especially informative about how quickly drug enters the systemic circulation. Later observations describe the net decline after the dose, but that decline does not always reveal elimination: with slow absorption, continuing input can control the apparent terminal slope. This is the source of flip-flop kinetics.
In individual forecasting, a fitted concentration curve can appear plausible while assigning uncertainty to the wrong rate constant. If a patient’s peak is later than expected, for example, the cause could be slower absorption, but a late sample alone may not establish that explanation. The timing and pattern of the available concentrations must be considered alongside the model and the information in the patient-specific distribution.
Model, Assumptions, and Peak Timing
For a single oral dose \(D\), assume linear pharmacokinetics, a constant bioavailability \(F\), a one-compartment disposition model, first-order absorption and elimination, and no absorption lag. Let \(V\) be the apparent volume of distribution. With concentration measured at time \(t\) after dosing, the model is
Here \(FD/V\) has concentration units, while the rate constants and time must use compatible units. This expression presumes a correctly recorded dose time and that the observed concentration corresponds to the modeled dose. For repeated dosing, concentrations from earlier doses can contribute; the single-dose curve should not be applied as if those contributions were absent.
The peak time follows by differentiating the concentration curve. Writing \(A=(FD/V)k_a/(k_a-k_e)\), the derivative is \(A(-k_e e^{-k_e t}+k_a e^{-k_a t})\). Setting it to zero gives \(k_a e^{-k_a t}=k_e e^{-k_e t}\), and therefore
For positive unequal rate constants this time is positive, whether \(k_a\) is greater or less than \(k_e\). A smaller \(k_a\), with other parameters fixed, generally delays the rise and peak. However, \(t_{\max}\) depends on both rate constants, so peak timing alone is not a direct measurement of \(k_a\).
When \(k_a=k_e=k\), the displayed expression for concentration has a zero denominator but the concentration itself has a finite limit: \(C(t)=(FD/V)kt e^{-kt}\). Thus, a numerical implementation should handle equal or nearly equal rates using a stable limiting calculation, rather than interpreting the denominator as a biological singularity.
Worked Example: Using the Peak and an Early Sample
Suppose a hypothetical single oral dose has \(FD/V=100\) mg/L, \(k_a=1.20\) h\(^{-1}\), and \(k_e=0.150\) h\(^{-1}\). Assume the stated dose time is correct and the one-compartment, first-order model applies. Find \(t_{\max}\) and the predicted concentration at 0.50 h.
The rates are distinct and positive, so the peak-time expression applies:
At 0.50 h, substitute the same rates and concentration scale:
The sample is predicted to occur before the peak, so it lies in the absorption-and-distribution rise of this model. It can inform \(k_a\), but it does not determine \(k_a\) by itself: the predicted value also depends on the dose scale and \(k_e\), and a single noisy observation cannot uniquely establish all these quantities.
Why the Terminal Slope Can Be Ambiguous
At late times, one exponential term in the oral model becomes much smaller than the other. If \(k_a>k_e\), then \(e^{-k_a t}\) decays faster, and the remaining tail is approximately proportional to \(e^{-k_e t}\). In this usual ordering, the terminal slope can reflect elimination. But if \(k_a<k_e\), then \(e^{-k_e t}\) decays faster; the remaining tail is approximately proportional to \(e^{-k_a t}\). In that case the terminal slope reflects slow absorption.
This result explains why an oral terminal slope cannot automatically be called an elimination rate. The oral curve can reveal the slower of the two processes in its terminal phase, while the faster rate may have little direct influence on that late tail. The ordering of the rates needs evidence beyond a straight-looking terminal segment.
Worked Example: A Terminal Slope Under Flip-Flop Kinetics
Consider a hypothetical oral dose with \(FD/V=100\) mg/L, \(k_a=0.120\) h\(^{-1}\), and \(k_e=0.800\) h\(^{-1}\). These positive, distinct rates satisfy \(k_a<k_e\), so this is a flip-flop case under the stated model. Calculate concentrations at 12 and 24 h and use them to estimate the interval slope.
At 12 h:
At 24 h:
The apparent decline rate between these times is
The late slope is close to \(k_a=0.120\) h\(^{-1}\), not to \(k_e=0.800\) h\(^{-1}\). A terminal-slope analysis that labels this value as elimination would substantially mischaracterize the hypothetical patient’s kinetics.
Using Samples to Separate the Rate Constants
The practical question is not whether an early or late sample is universally “best,” but which competing parameter explanations produce distinguishable predictions at the sampling times. An early sample on the rising limb can be sensitive to absorption rate. A sufficiently late sample can inform the terminal rate, but its interpretation depends on which process is slower. Samples around the peak and on both sides of it help describe the curve’s shape and reduce reliance on any one phase.
The earlier material on Bayesian forecasts at steady state establishes the role of patient concentrations in updating individual predictions. In this setting, it is useful to compare how candidate values of \(k_a\) and \(k_e\) change predictions at the actual sampling times. Such comparisons are not a substitute for a valid model or patient-specific uncertainty assessment; they show whether the data have leverage to distinguish the candidate explanations.
Worked Example: Is the Mismatch More Consistent With Absorption or Elimination?
For illustration, suppose hypothetical observations after a modeled oral dose are 43.3 mg/L at 0.50 h and 46.4 mg/L at 6 h. Use \(FD/V=100\) mg/L as a fixed scale. Compare a reference model (\(k_a=1.20\), \(k_e=0.150\) h\(^{-1}\)) with alternatives that change one rate at a time. All rates are positive and distinct, and all predictions use the same single-dose model.
The reference predictions are 43.31 mg/L at 0.50 h and 46.38 mg/L at 6 h. If absorption is slower (\(k_a=0.600\), \(k_e=0.150\) h\(^{-1}\)), then
and at 6 h,
Thus this slower-absorption alternative predicts a much lower early concentration and a somewhat higher 6-hour concentration than the reference. Now retain \(k_a=1.20\) h\(^{-1}\) but change elimination. With \(k_e=0.120\) h\(^{-1}\), the predictions are 43.66 mg/L at 0.50 h and 54.00 mg/L at 6 h. With \(k_e=0.180\) h\(^{-1}\), they are 42.96 mg/L at 0.50 h and 39.86 mg/L at 6 h.
In this illustration, the early prediction changes relatively little under the elimination alternatives, while the late prediction changes substantially. The slow-absorption alternative makes a distinctive early prediction. The two observations are therefore more useful for separating these candidate explanations than either one alone. This is a comparison of model predictions, not a formal claim that one rate is known exactly: measurement error, uncertainty in \(FD/V\), and model misspecification remain relevant.
Sampling Choices, Diagnostics, and Limits
A useful design includes observations that cover different parts of the concentration-time curve, when clinically and operationally feasible. A sample taken too early may be close to zero and highly sensitive to exact dose time, lag, and assay error. A sample taken near the peak can help locate its timing and height. Samples after the peak describe decline, while late samples can characterize the terminal behavior only if the relevant tail is observed and the input history is adequately represented.
When assessing an individual fit, ask whether residuals show a systematic pattern across time. Consistent underprediction during the rise and overprediction near the peak may indicate that the absorption timing or shape is wrong. A late decline that differs systematically from the fitted curve may signal a rate mismatch, but it can also reflect unmodeled input, an inaccurate dose time, or a structural feature absent from the model. Do not infer a rate constant from one residual or one concentration.
The formula and interpretations above depend on the stated assumptions. A lag time, transit or delayed absorption, multiple absorption phases, nonlinear elimination, changing bioavailability, or incorrect dose history can alter the curve. Repeated doses can overlap, so an apparent “early” sample after one dose may also contain drug from earlier doses. In such circumstances, early sampling is not automatically a clean measurement of \(k_a\); the model must represent the relevant inputs and processes.
The main alternatives differ in the information they emphasize. A terminal-slope approach summarizes late decline but risks assigning the slower process to the wrong mechanism. A peak-and-trough approach uses concentrations at widely separated times but can leave absorption timing poorly resolved if the peak is not observed. A model-based comparison across absorption, peak, and decline phases can use the full pattern, but it relies on the assumed structural model and adequate patient-specific information.
| Evidence used | What it can inform | Main limitation |
|---|---|---|
| Rising-phase sample | Absorption timing and candidate \(k_a\) values | Can be sensitive to dose-time error, lag, and scale uncertainty |
| Peak-region samples | Peak timing and curve shape | A single peak observation may not locate the peak reliably |
| Late samples | Terminal decline rate | May reflect \(k_a\) rather than \(k_e\) under flip-flop kinetics |
| Samples spanning phases | Contrasts alternative \(k_a\) and \(k_e\) explanations | Requires a suitable model and correctly represented dose inputs |
Common Pitfall
Wrong reasoning: “The log concentration curve is straight late after an oral dose, so its slope is the patient’s elimination rate.” A straight terminal segment establishes an apparent exponential decline over that interval; it does not establish which rate constant generated it. If \(k_a<k_e\), the terminal slope is governed by absorption.
Correction: Interpret the terminal slope in the context of the oral model and the ordering of \(k_a\) and \(k_e\). Examine whether observations during absorption and around the peak can distinguish competing rate assignments, and consider whether the assumptions about dose timing and absorption are credible. If the data do not distinguish the alternatives, report the ambiguity rather than treating one parameter interpretation as established.
Check Your Understanding
Answer each question, then compare with the solutions below.
- A hypothetical oral model has \(k_a=0.10\) h\(^{-1}\) and \(k_e=0.70\) h\(^{-1}\). Which rate primarily governs the terminal slope?
- For \(k_a=1.00\) h\(^{-1}\) and \(k_e=0.20\) h\(^{-1}\), calculate \(t_{\max}\).
- Why is a concentration measured before the expected peak potentially informative about \(k_a\), yet insufficient by itself to determine it?
- A fit matches late concentrations but systematically underpredicts concentrations on the rising phase. Give one rate-related explanation and one non-rate-related explanation to investigate.
Solutions. (1) Since \(k_a<k_e\), absorption is slower and primarily governs the terminal slope. (2) \(t_{\max}=\ln(1.00/0.20)/(1.00-0.20)=\ln(5)/0.80=2.012\) h. (3) The rising-phase shape depends on absorption, but the concentration also depends on the scale and elimination rate, and one observation is subject to error; it cannot uniquely identify \(k_a\). (4) A rate-related explanation is that the fitted \(k_a\) is too large, producing absorption that is too rapid. A non-rate-related explanation is an incorrectly recorded dose time or unmodeled absorption lag.